Home Cart 0 Sign in  

[ CAS No. 882772-99-8 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 882772-99-8
Chemical Structure| 882772-99-8
Structure of 882772-99-8 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 882772-99-8 ]

Related Doc. of [ 882772-99-8 ]

Alternatived Products of [ 882772-99-8 ]

Product Details of [ 882772-99-8 ]

CAS No. :882772-99-8 MDL No. :MFCD00462872
Formula : C7H4BrNO3 Boiling Point : -
Linear Structure Formula :- InChI Key :DAZQBQQNIUAQAV-UHFFFAOYSA-N
M.W : 230.02 Pubchem ID :21106434
Synonyms :

Calculated chemistry of [ 882772-99-8 ]

Physicochemical Properties

Num. heavy atoms : 12
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.0
Num. rotatable bonds : 2
Num. H-bond acceptors : 3.0
Num. H-bond donors : 0.0
Molar Refractivity : 48.35
TPSA : 62.89 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -6.35 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.18
Log Po/w (XLOGP3) : 1.9
Log Po/w (WLOGP) : 2.17
Log Po/w (MLOGP) : 1.02
Log Po/w (SILICOS-IT) : 0.51
Consensus Log Po/w : 1.36

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -2.7
Solubility : 0.458 mg/ml ; 0.00199 mol/l
Class : Soluble
Log S (Ali) : -2.84
Solubility : 0.33 mg/ml ; 0.00143 mol/l
Class : Soluble
Log S (SILICOS-IT) : -2.59
Solubility : 0.597 mg/ml ; 0.00259 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 3.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.82

Safety of [ 882772-99-8 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P280-P305+P351+P338 UN#:N/A
Hazard Statements:H302 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 882772-99-8 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 882772-99-8 ]
  • Downstream synthetic route of [ 882772-99-8 ]

[ 882772-99-8 ] Synthesis Path-Upstream   1~13

  • 1
  • [ 552-89-6 ]
  • [ 882772-99-8 ]
  • [ 5551-12-2 ]
  • [ 56990-05-7 ]
  • [ 20357-20-4 ]
  • [ 20357-21-5 ]
  • [ 1559060-83-1 ]
YieldReaction ConditionsOperation in experiment
20% at 25℃; for 3 h; Treatment of 1 (504 mg, 3.33 mmol) and NBS (1.48 g, 8.30 mmol) in H2SO4 (3.0 mL) as described above provided after purification by chromatography (hexanes/EtOAc, 85:15) the following fractions in order of elution: (I) 7 (65 mg, 0.21 mmol, 9percent); (II) 2 (153 mg, 20percent), 4 (58 mg, 8percent), and 6 (128 mg, 12percent); (III) 5 (108 mg, 14percent), 8 (129 mg, 13percent), and 1 (17 mg, 3percent); (IV) 3 (57 mg, 0.25 mmol, 8percent).
Reference: [1] Synthetic Communications, 2014, vol. 44, # 7, p. 954 - 958
  • 2
  • [ 552-89-6 ]
  • [ 882772-99-8 ]
  • [ 5551-12-2 ]
  • [ 56990-05-7 ]
  • [ 20357-20-4 ]
  • [ 20357-21-5 ]
  • [ 1559060-83-1 ]
YieldReaction ConditionsOperation in experiment
20% at 25℃; for 3 h; Treatment of 1 (504 mg, 3.33 mmol) and NBS (1.48 g, 8.30 mmol) in H2SO4 (3.0 mL) as described above provided after purification by chromatography (hexanes/EtOAc, 85:15) the following fractions in order of elution: (I) 7 (65 mg, 0.21 mmol, 9percent); (II) 2 (153 mg, 20percent), 4 (58 mg, 8percent), and 6 (128 mg, 12percent); (III) 5 (108 mg, 14percent), 8 (129 mg, 13percent), and 1 (17 mg, 3percent); (IV) 3 (57 mg, 0.25 mmol, 8percent).
Reference: [1] Synthetic Communications, 2014, vol. 44, # 7, p. 954 - 958
  • 3
  • [ 3132-99-8 ]
  • [ 882772-99-8 ]
  • [ 20357-20-4 ]
Reference: [1] Synthesis, 2008, # 14 SPEC. ISS., p. 2199 - 2210
  • 4
  • [ 552-89-6 ]
  • [ 882772-99-8 ]
  • [ 5551-12-2 ]
  • [ 56990-05-7 ]
  • [ 20357-20-4 ]
  • [ 20357-21-5 ]
  • [ 1559060-83-1 ]
YieldReaction ConditionsOperation in experiment
20% at 25℃; for 3 h; Treatment of 1 (504 mg, 3.33 mmol) and NBS (1.48 g, 8.30 mmol) in H2SO4 (3.0 mL) as described above provided after purification by chromatography (hexanes/EtOAc, 85:15) the following fractions in order of elution: (I) 7 (65 mg, 0.21 mmol, 9percent); (II) 2 (153 mg, 20percent), 4 (58 mg, 8percent), and 6 (128 mg, 12percent); (III) 5 (108 mg, 14percent), 8 (129 mg, 13percent), and 1 (17 mg, 3percent); (IV) 3 (57 mg, 0.25 mmol, 8percent).
Reference: [1] Synthetic Communications, 2014, vol. 44, # 7, p. 954 - 958
  • 5
  • [ 882772-99-8 ]
  • [ 145123-24-6 ]
Reference: [1] Synthesis, 2008, # 14 SPEC. ISS., p. 2199 - 2210
[2] Journal of the American Chemical Society, 2014, vol. 136, # 13, p. 4881 - 4884
[3] Inorganic Chemistry, 2015, vol. 54, # 16, p. 7873 - 7884
  • 6
  • [ 3132-99-8 ]
  • [ 882772-99-8 ]
YieldReaction ConditionsOperation in experiment
48% at 0 - 20℃; for 1.33333 h; A solution of nitric acid (0.6mL), and concentrated sulfuric acid (8.1mL), was stirred at 0°C, then 6a (3.0g, 0.11mmol) was added over a period of 20min. The mixture was stirred at rt for 1h and then poured into ice. The white solid formed was filtered and washed with water. The crude product was purified by flash chromatography (1:4, EtOAc/n-hexane) to obtain title compound as white solid (yield 48percent). 1H NMR (300MHz, CDCl3) δ 7.60 (t, J=7.5Hz, 1H), 7.92 (d, J=2.4Hz, 1H), 7.94 (d, J=2.4Hz, 1H), 9.87 (s, 1H).
Reference: [1] European Journal of Medicinal Chemistry, 2013, vol. 70, p. 233 - 247
[2] Organic and Biomolecular Chemistry, 2018, vol. 16, # 28, p. 5113 - 5118
  • 7
  • [ 1261475-45-9 ]
  • [ 882772-99-8 ]
YieldReaction ConditionsOperation in experiment
67.7% With manganese(IV) oxide In 1,2-dichloro-ethaneReflux 14.0 g of 3-bromo-2-nitrobenzyl alcohol and 150 mL of 1,2-dichloroethane were placed in a three-necked flask, and 42.0 g of manganese dioxide was added thereto, followed by heating to reflux. After the reaction was completed, it was added to Celite, and the filtrate was concentrated.Column was isolated to give 9.4 g (67.7percent) of 3-bromo-2-nitrobenzaldehyde.
Reference: [1] Patent: CN103880683, 2018, B, . Location in patent: Paragraph 0024; 0033-0034; 0045
  • 8
  • [ 105205-49-0 ]
  • [ 882772-99-8 ]
Reference: [1] Patent: WO2010/145883, 2010, A1, . Location in patent: Page/Page column 51
[2] Journal of Medicinal Chemistry, 2012, vol. 55, # 21, p. 9089 - 9106,18
  • 9
  • [ 52414-97-8 ]
  • [ 882772-99-8 ]
Reference: [1] Tetrahedron, 2008, vol. 64, # 5, p. 856 - 865
[2] Journal of Medicinal Chemistry, 2012, vol. 55, # 21, p. 9089 - 9106,18
  • 10
  • [ 552-89-6 ]
  • [ 882772-99-8 ]
  • [ 5551-12-2 ]
  • [ 56990-05-7 ]
  • [ 20357-20-4 ]
  • [ 20357-21-5 ]
  • [ 1559060-83-1 ]
YieldReaction ConditionsOperation in experiment
20% at 25℃; for 3 h; Treatment of 1 (504 mg, 3.33 mmol) and NBS (1.48 g, 8.30 mmol) in H2SO4 (3.0 mL) as described above provided after purification by chromatography (hexanes/EtOAc, 85:15) the following fractions in order of elution: (I) 7 (65 mg, 0.21 mmol, 9percent); (II) 2 (153 mg, 20percent), 4 (58 mg, 8percent), and 6 (128 mg, 12percent); (III) 5 (108 mg, 14percent), 8 (129 mg, 13percent), and 1 (17 mg, 3percent); (IV) 3 (57 mg, 0.25 mmol, 8percent).
Reference: [1] Synthetic Communications, 2014, vol. 44, # 7, p. 954 - 958
  • 11
  • [ 3132-99-8 ]
  • [ 882772-99-8 ]
  • [ 20357-20-4 ]
Reference: [1] Synthesis, 2008, # 14 SPEC. ISS., p. 2199 - 2210
  • 12
  • [ 13402-32-9 ]
  • [ 882772-99-8 ]
Reference: [1] Patent: CN103880683, 2018, B,
  • 13
  • [ 400629-31-4 ]
  • [ 882772-99-8 ]
Reference: [1] Patent: CN103880683, 2018, B,
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 882772-99-8 ]

Aryls

Chemical Structure| 20357-20-4

[ 20357-20-4 ]

5-Bromo-2-nitrobenzaldehyde

Similarity: 0.92

Chemical Structure| 163596-75-6

[ 163596-75-6 ]

4-Bromo-3-nitrobenzaldehyde

Similarity: 0.91

Chemical Structure| 116529-61-4

[ 116529-61-4 ]

3-Bromo-2-nitrobenzoic acid

Similarity: 0.90

Chemical Structure| 90407-21-9

[ 90407-21-9 ]

2-Bromo-3-nitrobenzaldehyde

Similarity: 0.87

Chemical Structure| 1807208-72-5

[ 1807208-72-5 ]

4-Bromo-3-methyl-5-nitrobenzamide

Similarity: 0.85

Bromides

Chemical Structure| 20357-20-4

[ 20357-20-4 ]

5-Bromo-2-nitrobenzaldehyde

Similarity: 0.92

Chemical Structure| 163596-75-6

[ 163596-75-6 ]

4-Bromo-3-nitrobenzaldehyde

Similarity: 0.91

Chemical Structure| 116529-61-4

[ 116529-61-4 ]

3-Bromo-2-nitrobenzoic acid

Similarity: 0.90

Chemical Structure| 90407-21-9

[ 90407-21-9 ]

2-Bromo-3-nitrobenzaldehyde

Similarity: 0.87

Chemical Structure| 1807208-72-5

[ 1807208-72-5 ]

4-Bromo-3-methyl-5-nitrobenzamide

Similarity: 0.85

Aldehydes

Chemical Structure| 20357-20-4

[ 20357-20-4 ]

5-Bromo-2-nitrobenzaldehyde

Similarity: 0.92

Chemical Structure| 163596-75-6

[ 163596-75-6 ]

4-Bromo-3-nitrobenzaldehyde

Similarity: 0.91

Chemical Structure| 90407-21-9

[ 90407-21-9 ]

2-Bromo-3-nitrobenzaldehyde

Similarity: 0.87

Chemical Structure| 355134-13-3

[ 355134-13-3 ]

3-Bromo-5-nitrobenzaldehyde

Similarity: 0.83

Chemical Structure| 101682-68-2

[ 101682-68-2 ]

3-Bromo-4-nitrobenzaldehyde

Similarity: 0.83

Nitroes

Chemical Structure| 20357-20-4

[ 20357-20-4 ]

5-Bromo-2-nitrobenzaldehyde

Similarity: 0.92

Chemical Structure| 163596-75-6

[ 163596-75-6 ]

4-Bromo-3-nitrobenzaldehyde

Similarity: 0.91

Chemical Structure| 116529-61-4

[ 116529-61-4 ]

3-Bromo-2-nitrobenzoic acid

Similarity: 0.90

Chemical Structure| 90407-21-9

[ 90407-21-9 ]

2-Bromo-3-nitrobenzaldehyde

Similarity: 0.87

Chemical Structure| 1807208-72-5

[ 1807208-72-5 ]

4-Bromo-3-methyl-5-nitrobenzamide

Similarity: 0.85